Evidence map›Paper›PMID 40157953›Full record

ArticleNPJ vaccines2025

Modeling the impact of early vaccination in an influenza pandemic in the United States.

Van Hung Nguyen, Pascal Crépey, B Adam Williams, Verna L Welch, Jean Marie Pivette, Charles H Jones, Jane M True

Abstract read
In one paragraph

Article in NPJ vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Van Hung NguyenVHN Consulting Inc, Montreal, QC, Canada.
Pascal CrépeyEHESP, University of Rennes, CNRS, IEP Rennes, Arènes-UMR 6051, RSMS-Inserm U 1309, Rennes, France.ORCID http://orcid.org/0000-0003-1852-0752
B Adam WilliamsPfizer, New York, NY, USA.ORCID http://orcid.org/0009-0001-1558-9562
Verna L WelchPfizer, New York, NY, USA.
Jean Marie PivetteVHN Consulting Inc, Montreal, QC, Canada.
Charles H JonesPfizer, New York, NY, USA.ORCID http://orcid.org/0009-0004-0368-6463
Jane M TruePfizer, New York, NY, USA. janemtrue@gmail.com.

Funding

Pfizer (Pfizer Inc.) n/a
6 · The paper itself

Abstract

We modeled the impact of initiating one-dose influenza vaccination at 3 months vs 6 months after declaration of a pandemic over a 1-year timeframe in the US population. Three vaccine effectiveness (VE) and two pandemic severity levels were considered, using an epidemic curve based on typical seasonal influenza epidemics. Vaccination from 3 months with a high, moderate, or low effectiveness vaccine would prevent ~95%, 84%, or 38% deaths post-vaccination, respectively, compared with 21%, 18%, and 8%, respectively following vaccination at 6 months, irrespective of pandemic severity. While the pandemic curve would not be flattened from vaccination from 6 months, a moderate/high effectiveness vaccine could flatten the curve if administered from 3 months. Overall, speed of initiating a vaccination campaign is more important than VE in reducing the health impacts of an influenza pandemic. Preparedness strategies may be able to minimize future pandemic impacts by prioritizing rapid vaccine roll-out.

Identifiers

PMID40157953
PMCPMC11954890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.